Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma. - Choi SB; Lee HT; Gu N; Jang YJ; Park UB; Jeong TJ; Lee SH; Heo YS (International journal of molecular sciences, 2025)